General Nurse Practitioner News

NP

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vieillard-Baron A et al. - The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.

Related Articles

Standardized order sets for the treatment of severe sepsis and septic shock
Expert Review of Anti-infective Therapy, 11/12/09    Relevance Score: 69%

An explorative study on quality of life and psychological and cognitive function in pediatric survivors of septic shock
Pediatric Critical Care, 11/10/09    Relevance Score: 69%

Corticosteroids for severe sepsis and septic shock
Intensivmedizin und Notfallmedizin, 11/06/09    Relevance Score: 69%

Is pituitary failure the real therapeutic target in septic shock
Medical Hypotheses, 11/04/09    Relevance Score: 69%

Beta-2-Adrenergic Receptor Gene Polymorphism is Associated with Mortality in Septic Shock
American Journal of Respiratory and Critical Care Medicine, 10/27/09    Relevance Score: 68%

Today in Clinical Pharmacology...keeping you current

The Statin Choice decision aid in primary care: A randomized trial
Patient Education and Counselling, 12/04/09

Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
Cleveland Clinic Journal of Medicine, 12/04/09

Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?
Cleveland Clinic Journal of Medicine, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address